Vandetanib

CAS 443913-73-3

Also known as: Vandetanib Base

Vandetanide is a multi-target tyrosine kinase inhibitor, belonging to anilinoquinozoline compounds, known as "second generation Iressa". It not only acts on EGFR, VEGFR and RET tyrosine kinases of tumor cells, but also inhibits other tyrosine kinases and serine / threonine kinases. Vandetanide is the first approved medulloid thyroid cancer treatment drug, suitable for the treatment of unresectable, locally advanced or metastatic medulloid thyroid cancer with symptoms or progression. In a randomized, placebo-controlled clinical trial, vandetanib significantly delayed the progression of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300mg (oral), and the treatment should be stopped when the patient has tolerance to the drug or cannot tolerate its toxicity. The most common adverse reactions are diarrhea, rash, acne, nausea, hypertension, headache, fatigue, anorexia and abdominal pain.

Request a Quote
Category: Pharmaceutical Chemicals APISubcategory: Antineoplastic Drugs APIProduct ID: vandetanib-443913-73-3
Payment & Shipping Terms Supply Capacity
Payment Terms: T/T, WU Production Capacity: 1000kg/year
Min. Order: 1 Gram Packing: according to the customer's requirements
Means of Transport: Ocean, Air, Land Delivery Date: 7 days

Vandetanib

CAS 443913-73-3

Vandetanide is a multi-target tyrosine kinase inhibitor, belonging to anilinoquinozoline compounds, known as "second generation Iressa". It not only acts on EGFR, VEGFR and RET tyrosine kinases of tumor cells, but also inhibits other tyrosine kinases and serine / threonine kinases. Vandetanide is the first approved medulloid thyroid cancer treatment drug, suitable for the treatment of unresectable, locally advanced or metastatic medulloid thyroid cancer with symptoms or progression. In a randomized, placebo-controlled clinical trial, vandetanib significantly delayed the progression of locally advanced or metastatic medullary thyroid cancer. The recommended daily dose is 300mg (oral), and the treatment should be stopped when the patient has tolerance to the drug or cannot tolerate its toxicity. The most common adverse reactions are diarrhea, rash, acne, nausea, hypertension, headache, fatigue, anorexia and abdominal pain.

We can customize according to customer's requirement

if you have any question pls mail us or call us.

CAS Number 443913-73-3
Molecular Formula C22H24BrFN4O2
Molecular Weight 475.35
Place of Origin Shandong,China (Mainland)
Brand MOSINTER
Specification CP/USP/EP
Content 95%min
Request a quote

Send an inquiry for Vandetanib

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

×
MOSINTER chemical operations

Request a Quote

By sending this inquiry, you acknowledge our Privacy Policy. We use these details only to answer your request.

We usually respond within one business day.

MOSINTER GROUP